BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 34140952)

  • 1. B7-H7 Is Inducible on T Cells to Regulate Their Immune Response and Serves as a Marker for Exhaustion.
    Luu K; Schwarz H; Lundqvist A
    Front Immunol; 2021; 12():682627. PubMed ID: 34140952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenotypical and potential functional characteristics of different immune cells expressing CD28H/B7-H5 and their relationship with cancer prognosis.
    Zhong C; Lang Q; Yu J; Wu S; Xu F; Tian Y
    Clin Exp Immunol; 2020 Apr; 200(1):12-21. PubMed ID: 31901178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B7-H7 (HHLA2) inhibits T-cell activation and proliferation in the presence of TCR and CD28 signaling.
    Rieder SA; Wang J; White N; Qadri A; Menard C; Stephens G; Karnell JL; Rudd CE; Kolbeck R
    Cell Mol Immunol; 2021 Jun; 18(6):1503-1511. PubMed ID: 32005952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble B7-CD28 Family Inhibitory Immune Checkpoint Proteins and Anti-Cancer Immunotherapy.
    Khan M; Arooj S; Wang H
    Front Immunol; 2021; 12():651634. PubMed ID: 34531847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD28 Homolog Is a Strong Activator of Natural Killer Cells for Lysis of B7H7
    Zhuang X; Long EO
    Cancer Immunol Res; 2019 Jun; 7(6):939-951. PubMed ID: 31018957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T Cell Activation Pathways: B7, LFA-3, and ICAM-1 Shape Unique T Cell Profiles.
    Wingren AG; Parra E; Varga M; Kalland T; Sjogren HO; Hedlund G; Dohlsten M
    Crit Rev Immunol; 2017; 37(2-6):463-481. PubMed ID: 29773030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3.
    Janakiram M; Shah UA; Liu W; Zhao A; Schoenberg MP; Zang X
    Immunol Rev; 2017 Mar; 276(1):26-39. PubMed ID: 28258693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Eukaryotic expression of recombinant B7-H3Ig protein and its effects on T cells].
    Chen L; Zhang G; Zhu Y; Zhang X
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Jan; 29(1):27-30. PubMed ID: 23294715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B7-H5 costimulates human T cells via CD28H.
    Zhu Y; Yao S; Iliopoulou BP; Han X; Augustine MM; Xu H; Phennicie RT; Flies SJ; Broadwater M; Ruff W; Taube JM; Zheng L; Luo L; Zhu G; Chen J; Chen L
    Nat Commun; 2013; 4():2043. PubMed ID: 23784006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New B7 Family Checkpoints in Human Cancers.
    Ni L; Dong C
    Mol Cancer Ther; 2017 Jul; 16(7):1203-1211. PubMed ID: 28679835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential expression of B7 co-stimulatory molecules by astrocytes correlates with T cell activation and cytokine production.
    Soos JM; Ashley TA; Morrow J; Patarroyo JC; Szente BE; Zamvil SS
    Int Immunol; 1999 Jul; 11(7):1169-79. PubMed ID: 10383950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intact B7-H3 signaling promotes allograft prolongation through preferential suppression of Th1 effector responses.
    Ueno T; Yeung MY; McGrath M; Yang S; Zaman N; Snawder B; Padera RF; Magee CN; Gorbatov R; Hashiguchi M; Azuma M; Freeman GJ; Sayegh MH; Najafian N
    Eur J Immunol; 2012 Sep; 42(9):2343-53. PubMed ID: 22733595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FcR cross-linking on monocytes results in impaired T cell stimulatory capacity.
    Barcy S; Wettendorff M; Leo O; Urbain J; Kruger M; Ceuppens JL; de Boer M
    Int Immunol; 1995 Feb; 7(2):179-89. PubMed ID: 7537534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The expression, function, and clinical relevance of B7 family members in cancer.
    Seliger B; Quandt D
    Cancer Immunol Immunother; 2012 Aug; 61(8):1327-41. PubMed ID: 22695874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Butyrophilin-like 2 modulates B7 costimulation to induce Foxp3 expression and regulatory T cell development in mature T cells.
    Swanson RM; Gavin MA; Escobar SS; Rottman JB; Lipsky BP; Dube S; Li L; Bigler J; Wolfson M; Arnett HA; Viney JL
    J Immunol; 2013 Mar; 190(5):2027-35. PubMed ID: 23359506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the B7 family of co-stimulatory molecules: successes and challenges.
    Podojil JR; Miller SD
    BioDrugs; 2013 Feb; 27(1):1-13. PubMed ID: 23329394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B7-h3 and its role in antitumor immunity.
    Loos M; Hedderich DM; Friess H; Kleeff J
    Clin Dev Immunol; 2010; 2010():683875. PubMed ID: 21127709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Positive and Negative Immunoregulatory Role of B7 Family: Promising Novel Targets in Gastric Cancer Treatment.
    Bolandi N; Derakhshani A; Hemmat N; Baghbanzadeh A; Asadzadeh Z; Afrashteh Nour M; Brunetti O; Bernardini R; Silvestris N; Baradaran B
    Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule.
    Hombach A; Wieczarkowiecz A; Marquardt T; Heuser C; Usai L; Pohl C; Seliger B; Abken H
    J Immunol; 2001 Dec; 167(11):6123-31. PubMed ID: 11714771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BTNL8, a butyrophilin-like molecule that costimulates the primary immune response.
    Chapoval AI; Smithson G; Brunick L; Mesri M; Boldog FL; Andrew D; Khramtsov NV; Feshchenko EA; Starling GC; Mezes PS
    Mol Immunol; 2013 Dec; 56(4):819-28. PubMed ID: 24036152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.